ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Wren debuts to tackle protein misfolding

by Michael McCoy
January 27, 2019 | APPEARED IN VOLUME 97, ISSUE 4

 

Wren Therapeutics has raised $23 million in series A financing to develop small-molecule and antibody drugs that target protein misfolding diseases, including Alzheimer’s and Parkinson’s. The Cambridge, England-based firm was founded in 2016 by chemists and physicists at the University of Cambridge and Lund University. Wren says it uses concepts from the physical sciences, rather than biology, to uncover the chemical kinetics of protein misfolding.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment